Figure 5 PCBAT with peanut allergen extracts on peanut allergic
and peanut tolerant subjects
PCBAT using peanut allergen extracts (1, 10, 100 or 1000 ng/ml) were
performed on (A) 30 subjects with physician diagnosed peanut allergy,
and (B) on 4 atopic but non-peanut sensitized subjects. The relationship
between the PCBAT AUC from the sensitized groups and the corresponding
whole peanut sIgE level Ara h 1 sIgE level and Ara h 2 sIgE level were
shown in scatter plot (C-E respectively). Fifteen out of 30 sensitized
subjects underwent oral food challenge. The relationship between
cumulative peanut dose to show first objective sign and PCBAT AUC or
sIgE to whole peanut, Ara h 1 and Ara h 2 were shown in F-I
respectively. (J) 13 peanut sensitized but tolerant subjects. Anti-IgE
was used as positive control stimulant for all tested serum samples.
Spearman test and R square was calculated, p<0.05 were
considered significant.